| Halim Fadil, MD | |
|
801 Road To Six Flags W Ste 127, Arlington, TX 76012-2600 | |
| (817) 697-8000 | |
| Not Available |
| Full Name | Halim Fadil |
|---|---|
| Gender | Male |
| Speciality | Neurology |
| Experience | 29 Years |
| Location | 801 Road To Six Flags W Ste 127, Arlington, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1982814570 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Northwest Texas Hospital | Amarillo, TX | Hospital |
| Entity Name | Acclaim Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780076562 PECOS PAC ID: 4587963582 Enrollment ID: O20160426000707 |
News Archive
Astellas Pharma US, Inc., U.S. subsidiary of Astellas Pharma Inc., today announced the results of a pivotal phase III clinical trial for mirabegron, the first of a new class of compounds under development for the treatment of overactive bladder (OAB), which show mirabegron significantly improves key OAB symptoms – urinary incontinence and frequency of micturition compared with placebo.
Eclipsys Corporation®, The Outcomes Company®, today announced that the Certification Commission for Health Information Technology (CCHIT®) has listed its PeakPractice™ solution (version 1093) a CCHIT Certified® 08 Ambulatory electronic health record (EHR), and meets the Certification Commission's EHR criteria for office-based use.
New research in the November 2019 issue of JNCCN—Journal of the National Comprehensive Cancer Network examines the implications of invasive breast cancer after breast-conserving treatment for ductal carcinoma in situ (aka DCIS, a form of non-invasive breast cancer) and which factors could impact overall survival.
Fibrin, the chief ingredient of blood clots, is a remarkably versatile polymer. On one hand, it forms a network of fibers - a blood clot - that stems the loss of blood at an injury site while remaining pliable and flexible. On the other hand, fibrin provides a scaffold for thrombi, clots that block blood vessels and cause tissue damage, leading to myocardial infarction, ischemic stroke, and other cardiovascular diseases. How does fibrin manage to be so strong and yet so extensible under the stresses of healing and blood flow?
› Verified 7 days ago
| Entity Name | Neurology And Movement Disorders Center Of North Texas |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992244719 PECOS PAC ID: 0042594111 Enrollment ID: O20170309001026 |
News Archive
Astellas Pharma US, Inc., U.S. subsidiary of Astellas Pharma Inc., today announced the results of a pivotal phase III clinical trial for mirabegron, the first of a new class of compounds under development for the treatment of overactive bladder (OAB), which show mirabegron significantly improves key OAB symptoms – urinary incontinence and frequency of micturition compared with placebo.
Eclipsys Corporation®, The Outcomes Company®, today announced that the Certification Commission for Health Information Technology (CCHIT®) has listed its PeakPractice™ solution (version 1093) a CCHIT Certified® 08 Ambulatory electronic health record (EHR), and meets the Certification Commission's EHR criteria for office-based use.
New research in the November 2019 issue of JNCCN—Journal of the National Comprehensive Cancer Network examines the implications of invasive breast cancer after breast-conserving treatment for ductal carcinoma in situ (aka DCIS, a form of non-invasive breast cancer) and which factors could impact overall survival.
Fibrin, the chief ingredient of blood clots, is a remarkably versatile polymer. On one hand, it forms a network of fibers - a blood clot - that stems the loss of blood at an injury site while remaining pliable and flexible. On the other hand, fibrin provides a scaffold for thrombi, clots that block blood vessels and cause tissue damage, leading to myocardial infarction, ischemic stroke, and other cardiovascular diseases. How does fibrin manage to be so strong and yet so extensible under the stresses of healing and blood flow?
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Halim Fadil, MD 801 Road To Six Flags W Ste 127, Arlington, TX 76012-2600 Ph: (817) 697-8000 | Halim Fadil, MD 801 Road To Six Flags W Ste 127, Arlington, TX 76012-2600 Ph: (817) 697-8000 |
News Archive
Astellas Pharma US, Inc., U.S. subsidiary of Astellas Pharma Inc., today announced the results of a pivotal phase III clinical trial for mirabegron, the first of a new class of compounds under development for the treatment of overactive bladder (OAB), which show mirabegron significantly improves key OAB symptoms – urinary incontinence and frequency of micturition compared with placebo.
Eclipsys Corporation®, The Outcomes Company®, today announced that the Certification Commission for Health Information Technology (CCHIT®) has listed its PeakPractice™ solution (version 1093) a CCHIT Certified® 08 Ambulatory electronic health record (EHR), and meets the Certification Commission's EHR criteria for office-based use.
New research in the November 2019 issue of JNCCN—Journal of the National Comprehensive Cancer Network examines the implications of invasive breast cancer after breast-conserving treatment for ductal carcinoma in situ (aka DCIS, a form of non-invasive breast cancer) and which factors could impact overall survival.
Fibrin, the chief ingredient of blood clots, is a remarkably versatile polymer. On one hand, it forms a network of fibers - a blood clot - that stems the loss of blood at an injury site while remaining pliable and flexible. On the other hand, fibrin provides a scaffold for thrombi, clots that block blood vessels and cause tissue damage, leading to myocardial infarction, ischemic stroke, and other cardiovascular diseases. How does fibrin manage to be so strong and yet so extensible under the stresses of healing and blood flow?
› Verified 7 days ago
John R Marshall, DO Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1107 N Cooper St, Arlington, TX 76011 Phone: 817-860-6067 Fax: 817-860-6016 | |
Dr. Annette Marie Shelton, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 2011 E Lamar Blvd Ste 100, Arlington, TX 76006 Phone: 817-548-0504 Fax: 817-861-8845 | |
Mr. Sajish Eapen Jacob, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 811 W Interstate 20 Ste 224, Arlington, TX 76017 Phone: 817-641-6000 Fax: 817-419-4501 | |
Dr. Rajendra P Gandhi, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 912 Wright St, Suite B, Arlington, TX 76012 Phone: 817-274-7593 Fax: 817-261-4785 | |
Dr. Jacqueline Geneva Curtis, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 3901 Arlington Highlands Blvd, Ste 200, Arlington, TX 76018 Phone: 817-719-3736 | |
Dr. Sylvia Arlene Moring, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1715 Venetian Cir, Arlington, TX 76013 Phone: 817-795-7222 | |
Dr. Robert Charles Knipstein, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 731 N Fielder, Suite 100, Arlington, TX 76012 Phone: 817-265-2021 Fax: 817-265-3410 |